Focal Hypertrichosis during Topical Tacrolimus Therapy for Vitiligo: A Case Report

Introduction: Tacrolimus is widely used in treating vitiligo. Drug-induced hypertrichosis is a well-known side effect of cyclosporine. It is less commonly associated with tacrolimus or with topical calcineurin inhibitors. Four reports of hypertrichosis attributed to topical or systemic tacrolimus ha...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in dermatology Vol. 17; no. 1; pp. 106 - 109
Main Authors: Mao, Lingyu, Lin, Yan, Yu, Xueping, Liu, Huaxu
Format: Journal Article
Language:English
Published: Switzerland S. Karger AG 01.04.2025
Karger Publishers
Subjects:
Single Case
Tacrolimus
Hypertrichosis
Vitiligo
ISSN:1662-6567, 1662-6567
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Tacrolimus is widely used in treating vitiligo. Drug-induced hypertrichosis is a well-known side effect of cyclosporine. It is less commonly associated with tacrolimus or with topical calcineurin inhibitors. Four reports of hypertrichosis attributed to topical or systemic tacrolimus have been previously reported in the literature. In this report, we describe a case of focal hypertrichosis due to long-term use of topical tacrolimus for vitiligo. Case Presentation: We present a 15-year-old boy with focal hypertrichosis of white hair for 4 months, after treatment with topical tacrolimus 0.1% ointment. He denied ever using other ointment to the area. After he stopped using tacrolimus for half a month, the focal hypertrichosis improved. Conclusion: We propose that the focal hypertrichosis was induced by tacrolimus. The hair growth-stimulating effects of tacrolimus have been established. It is reported that tacrolimus directly stimulates mouse whiskers in vitro and prolongs the anagen phase of hair growth when it is applied topically in mice. We believe that a greater awareness of this rare side effect of tacrolimus is warranted as tacrolimus is widely used in treating vitiligo.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:1662-6567
1662-6567
DOI:10.1159/000545115